aTyr Pharma (NASDAQ:ATYR) Downgraded by HC Wainwright to Neutral

Key Points

• aTyr Pharma has been downgraded from a "buy" rating to a "neutral" rating by HC Wainwright, and other analysts have also issued negative ratings recently.
• The company's stock has plummeted 81.7% and is currently trading at $1.11, compared to a one-year high of $7.29.
• aTyr Pharma's quarterly earnings revealed a loss of ($0.22) earnings per share, missing analysts' estimates, and they are projected to have a EPS of -0.91 for the current year.

HC Wainwright lowered shares of aTyr Pharma (NASDAQ:ATYR - Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, MarketBeat Ratings reports. HC Wainwright also issued estimates for aTyr Pharma's FY2026 earnings at ($0.64) EPS, FY2027 earnings at ($0.72) EPS and FY2028 earnings at ($0.64) EPS.

ATYR has been the topic of a number of other research reports. Jefferies Financial Group raised their target price on shares of aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 22nd. Cantor Fitzgerald lowered shares of aTyr Pharma from an "overweight" rating to a "neutral" rating in a report on Monday. Wall Street Zen lowered shares of aTyr Pharma from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Leerink Partners reissued a "market perform" rating on shares of aTyr Pharma in a report on Monday. Finally, Wells Fargo & Company lifted their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, June 20th. One analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $23.25.

aTyr Pharma Trading Down 5.5%

aTyr Pharma stock traded down $0.06 during midday trading on Monday, reaching $0.99. The stock had a trading volume of 26,835,154 shares, compared to its average volume of 4,180,764. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $5.02 and a 200 day moving average of $4.30. aTyr Pharma has a 52-week low of $0.95 and a 52-week high of $7.29. The firm has a market cap of $97.21 million, a price-to-earnings ratio of -1.24 and a beta of 1.01.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). On average, analysts anticipate that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp purchased a new position in shares of aTyr Pharma during the 4th quarter worth $661,000. Jane Street Group LLC purchased a new stake in aTyr Pharma in the fourth quarter valued at approximately $720,000. Bank of America Corp DE purchased a new stake in aTyr Pharma in the fourth quarter valued at approximately $330,000. Balyasny Asset Management L.P. purchased a new stake in shares of aTyr Pharma in the 4th quarter valued at $160,000. Finally, Group One Trading LLC purchased a new stake in shares of aTyr Pharma in the 4th quarter valued at $26,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.